Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer

Huo, Jinhai; Chu, Yiyi; Chamie, Karim; Smaldone, Marc C.; Boorjian, Stephen A.; Baillargeon, Jacques; Kuo, Yong Fang; Kerr, Preston; O’Malley, Padraic; Orihuela, Eduardo; Tyler, Douglas S.; Freedland, Stephen J.; Giordano, Sharon H.; Vikram, Raghu; Kamat, Ashish M.; Williams, Stephen B.

doi:10.1016/j.clgc.2017.07.018

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radiotracer is injected approximately 60 min prior to the scan, and the patients are instructed to follow a specific diet and activity regimen prior to the exam to avoid muscle activity and alterations in radiotracer biodistribution due to endogenous insulin release. A review of the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2011 demonstrated that a total of 36,855 patients underwent a PET/CT scan for bladder cancer of any stage and that the number of scans markedly increased throughout the time period, resulting in excess national spending of $11.6 million for this imaging modality [46,47]. However, for patients with bladder cancer, FDG-PET/CT has the potential to change patient management, and patients with positive FDG-PET/CT scans demonstrate worse overall survival and higher recurrence rates in cases of recurrent disease [48].…”

Section: Why Pet/ct For Bladder Cancer?mentioning

confidence: 99%

The Role of Imaging in Bladder Cancer Diagnosis and Staging

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) is the most common cancer of the urinary tract in the United States. Imaging plays a significant role in the management of patients with BC, including the locoregional staging and evaluation for distant metastatic disease, which cannot be assessed at the time of cystoscopy and biopsy/resection. We aim to review the current role of cross-sectional and molecular imaging modalities for the staging and restaging of BC and the potential advantages and limitations of each imaging modality. CT is the most widely available and frequently utilized imaging modality for BC and demonstrates good performance for the detection of nodal and visceral metastatic disease. MRI offers potential value for the locoregional staging and evaluation of muscular invasion of BC, which is critically important for prognostication and treatment decision-making. FDG-PET/MRI is a novel hybrid imaging modality combining the advantages of both MRI and FDG-PET/CT in a single-setting comprehensive staging examination and may represent the future of BC imaging evaluation.

show abstract

Section: Why Pet/ct For Bladder Cancer?mentioning

confidence: 99%

The Role of Imaging in Bladder Cancer Diagnosis and Staging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In conclusion, the current literature suggests that 18F-FDG PET/CT provides an incremental value for nodal and distant staging in MIBC at initial diagnosis. However, due to its significant cost for healthcare systems ( 34 ), prospective studies with high evidence level are still needed before its use can be formally adopted into consensus guidelines and recommendations ( 3 , 18 , 35 , 36 ). In support of its role in distant staging, a recent consensus statement revealed that 18F-FDG PET/CT is the imaging modality of choice to avoid over-treatment in oligometastatic patients with an agreement of 88% of participants ( 37 ) ( Figure 1B ).…”

Section: Risk Stratification At Diagnosismentioning

confidence: 99%

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro- D -glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.

show abstract

“…However, use of F-18 FDG PET/CT in urinary system has developed slowly due to the uptake of F-18 FDG in urine. Though previous studies showed that delayed diuretic PET/CT could be used in the diagnosis of bladder cancer (12)(13)(14), only few studies investigated the value of F-18 FDG PET/CT in upper urinary tract-occupying lesions. Though the diagnostic sensitivity of F-18 FDG PET/CT for detecting metastasis was superior to CT in upper urinary tract carcinoma, it was not feasible to detect the primary tumor because of the radiotracer in the urine (15).…”

Section: Introductionmentioning

confidence: 99%

Use of F-18 FDG PET/CT Through Delayed Diuretic Imaging for Preoperative Evaluation of Upper Urinary Tract-Occupying Lesions

Wang

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo evaluate the value of F-18 FDG PET/CT in the differentiation of malignant and benign upper urinary tract-occupying lesions.Patients and Methods64 patients with upper urinary tract-occupying lesions underwent F-18 FDG PET/CT at RenJi Hospital from January 2015 to February 2019 in this retrospective study. Of the 64 patients, 50 patients received nephroureterectomy or partial ureterectomy; 14 patients received ureteroscopy and biopsy. The comparisons of PET/CT parameters and clinical characteristics between malignant and benign upper urinary tract-occupying lesions were investigated.ResultsOf the 64 patients, 49 were found to have malignant tumors. Receiver operating characteristic analysis determined the lesion SUVmax value of 6.75 as the threshold for predicting malignant tumors. There were significant associations between malignant and benign upper urinary tract-occupying lesions and SUVmax of lesion (P<0.001), lesion size (P<0.001), and patient age (P=0.011). Multivariate analysis showed that SUVmax of lesion (P=0.042) and patient age (P=0.009) as independent predictors for differentiation of malignant from benign upper urinary tract-occupying lesions. There was a significant difference in tumor size between the positive (SUVmax >6.75) and negative (SUVmax ≤6.75) PET groups in 38 of the 49 patients with malignant tumors.ConclusionThe SUVmax of lesion and patient age is associated with the nature of upper urinary tract-occupying lesions. F-18 FDG PET/CT may be useful to distinguish between malignant and benign upper urinary tract-occupying lesions and determine a suitable therapeutic strategy.

show abstract

Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer

Cited by 7 publications

References 29 publications

The Role of Imaging in Bladder Cancer Diagnosis and Staging

The Role of Imaging in Bladder Cancer Diagnosis and Staging

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

Use of F-18 FDG PET/CT Through Delayed Diuretic Imaging for Preoperative Evaluation of Upper Urinary Tract-Occupying Lesions

Contact Info

Product

Resources

About